Table 2 Baseline characteristics and laboratory findings of MHD patients with COVID-19 according to the disease severity
From: Determinants of mortality in a large group of hemodialysis patients hospitalized for COVID-19
|  | Mild-moderate disease (n = 297) | Severe-critical disease (n = 270) | p value |
|---|---|---|---|
Age (year) | 63 (52.00–71.00) | 64 (54.00–73.00) | 0.26 |
Hemodialysis duration (years) | 3 (1.40–6.00) | 3 (1.00–6.00) | 0.86 |
LDH (> 2 × upper limit of normal), DH | 47 (17.2) | 89 (34.5) | < 0.001 |
AST (> 2 × upper limit of normal), DH | 17 (5.9) | 58 (21.9) | < 0.001 |
Lymphopenia (< 1500/mm3), DH | 154 (52.7) | 189 (71.1) | < 0.001 |
Thrombocytopenia (< 150 × 103/mm3), DH | 56 (19.2) | 85 (31.6) | < 0.001 |
Fever, n (%) | 153 (51.5) | 153 (56.7) | 0.21 |
Dyspnea, n (%) | 90 (30.3) | 217 (80.4) | < 0.001 |
Dry cough, n (%) | 129 (43.4) | 130 (48.1) | 0.26 |
Fatigue, n (%) | 112 (37.7) | 123 (45.6) | 0.58 |
Myalgia, n (%) | 50 (16.8) | 52 (19.3) | 0.45 |
Headache, n (%) | 24 (8.1) | 22 (8.1) | 0.97 |
Sore throat, n (%) | 25 (8.4) | 20 (7.4) | 0.65 |
Anorexia, n (%) | 13 (4.4) | 24 (8.9) | 0.030 |
Diarrhea, n (%) | 13 (4.4) | 9 (3.3) | 0.52 |
No symptom, n (%) | 40 (13.5) | 2 (0.7) | < 0.001 |
ICU admission, n (%) | 19 (6.4) | 115 (42.5) | < 0.001 |
Mechanical ventilation need, n (%)* | 10 (52.6) | 81 (72.3) | 0.08 |
In-hospital mortality, n (%) | 11 (3.7) | 82 (30.4) | < 0.001 |